| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the Audit Committee of the Board (the “... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 23 Oct 2026 | SCHEDULE 13G |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip... |
| 01 Sep 2026 |
8-K: Regulation FD Disclosure
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 |
Form 4: Klickstein Lloyd, Director
Granted 18,300 Stock Option (Right to Buy) |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 mont... |
| 23 Jun 2026 |
Form 4: Schor Chen, Director
Granted 55,000 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Aftab Blake, Chief Scientific Officer
Granted 55,000 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Dubin Steve, Director
Granted 4,200 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Chodakewitz Jeffrey, Director
Granted 4,200 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Grissinger Michael, Director
Granted 4,200 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Sinclair Andrew, Director
Granted 4,200 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Peng Katie, Director
Granted 4,200 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Klickstein Lloyd, Director
Granted 4,200 Stock Option (Right to Buy) |
Loading...